key: cord-0697029-wclwsy0c
authors: Fan, Bingwen Eugene; Ramanathan, Kollengode; Sum, Christina Lai Lin; Christopher, Dheepa; Chan, Stephrene Seok Wei; Lim, Gek Hsiang; Bok, Chwee Fang; Wong, Shiun Woei; Lye, David Chien; Young, Barnaby Edward; Lim, Jia Yan; Lee, Rui Min; Lim, Shu Ping; Tan, Hwee Tat; Ang, Mui Kia; Lau, Soon Lee; Kuperan, Ponnudurai; Ong, Kiat Hoe; Chia, Yew Woon
title: Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study
date: 2021-09-28
journal: J Thromb Thrombolysis
DOI: 10.1007/s11239-021-02575-4
sha: c5028766ded39d46b644d23214913fbc387a90ab
doc_id: 697029
cord_uid: wclwsy0c

Severe COVID-19 patients demonstrate hypercoagulability, necessitating thromboprophylaxis. However, less is known about the haemostatic profile in mild COVID-19 patients. We performed an age and gender-matched prospective study of 10 severe and 10 mild COVID-19 patients. Comprehensive coagulation profiling together with Thromboelastography and Clot Waveform Analysis were performed. FBC, PT, APTT, D-dimer, fibrinogen and CWA were repeated every 3 days for both groups and repeat TEG was performed for severe patients up till 15 days. On recruitment, severe patients had markers reflecting hypercoagulability including raised median D-dimer 1.0 μg/mL (IQR 0.6, 1.4) (p = 0.0004), fibrinogen 5.6 g/L (IQR 4.9, 6.6) (p = 0.002), Factor VIII 206% (IQR 171, 203) and vWF levels 265.5% (IQR 206, 321). Mild patients had normal values of PT, aPTT, fibrinogen and D-dimer, and slightly elevated median Factor VIII and von Willebrand factor (vWF) levels. Repeated 3-day assessments for both groups showed declining trends in D-dimer and Fibrinogen. CWA of severe COVID-19 group demonstrated hypercoagulability with an elevated median values of aPTT delta change 78.8% (IQR 69.8, 85.2) (p = 0.001), aPTT clot velocity (min1) 7.8%/s (IQR 6.7, 8.3) (p = 0.001), PT delta change 22.4% (IQR 19.4, 29.5) (p = 0.004), PT min1 7.1%/s (IQR 6.3, 9.0) (p = 0.02), PT clot acceleration (min 2) 3.6%/s(2) (IQR 3.2, 4.5) (p = 0.02) and PT clot deceleration (max2) 2.9%/s(2) (IQR 2.5, 3.5) (p = 0.02). TEG of severe patients reflected hypercoagulability with significant increases in the median values of CFF MA 34.6 mm (IQR 27.4,38.6) (p = 0.003), CRT Angle 78.9° (IQR 78.3, 80.0) (p = 0.0006), CRT A10 67.6 mm (IQR 65.8, 69.6) (p = 0.007) and CFF A10 32.0 mm (IQR 26.8, 34.0) (p = 0.003). Mild COVID-19 patients had absent hypercoagulability in both CWA and TEG. 2 severe patients developed thromboembolic events while none occurred in the mild COVID-19 group. Mild COVID-19 patients show absent parameters of hypercoagulability in global haemostatic tests while those with severe COVID-19 demonstrated parameters associated with hypercoagulability on the global haemostatic tests together with raised D-Dimer, fibrinogen, Factor VIII and vWF levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-021-02575-4.

The COVID-19 pandemic remains a serious global health threat, with more virulent new variants emerging. While most COVID-19 infections are mild, a subset progress to severe or critical illness, characterized by acute respiratory distress syndrome, often accompanied with multiorgan failure. With the lungs as the thrombotic epicenter causing pulmonary intravascular coagulopathy, severe COVID-19 is characterized by a high incidence of macro and microvascular thromboembolic events due to COVID-19 associated coagulopathy (CAC) [1, 2] . This may be attributed to platelet activation, endothelial dysfunction, neutrophil extracellular traps and activation of the coagulation cascade, which are reflective of an uncontrolled proinflammatory response with immune dysregulation and rarely, cytokine storm, in these severe or critically ill patients with sepsis. While hypercoagulability [3] and a high incidence of thrombosis [4, 5] in severely ill COVID-19 patients has been well described, less is known about the haemostatic profile in patients with mild COVID-19 infection who are non-hypoxic with normal chest imaging.

CAC can be dynamic with some patients being prothrombotic while others can be at risk of bleeding. The coagulation derangements are more marked in those who are severely or critically ill, likely reflective of a higher burden of micro thrombosis which may precede overt organ failure. Early recognition of CAC and the prompt initiation of thromboprophylactic therapy may lower risk of thromboembolic disease and improve outcomes. While standard coagulation tests are useful as a baseline assessment of coagulation profile, they are not sensitive enough to detect hypercoagulable and mild hypocoagulable states. These tests also do not provide sufficient information to diagnose and treat patients timely and according to their phenotype. Global tests of haemostasis [6] [7] [8] such as clot waveform analysis (CWA) and viscoelastic testing using thromboelastography (TEG) [9] or rotational thromboelastometry (ROTEM) [10] are helpful in the dynamic assessment of haemostasis in acutely ill COVID-19 patients and can improve this assessment [11] .

The ISTH [12] and latest CHEST guidelines [13] on VTE and management in hospitalized COVID-19 patients have recommended a universal strategy of routine thromboprophylaxis with standard-dose UFH or LMWH after careful assessment of bleed risk, with the ISTH suggesting intermediate-dose LMWH may also be considered. While the ACTIV-4, REMAP-CAP and ATT ACC multicentre trials [14] studied therapeutic anticoagulation dose heparin versus standard prophylaxis in COVID-19 patients in the ICU or those who were moderately ill in the general ward, mildly ill COVID-19 patients who are hospitalized are underrepresented in ongoing trials with a lack of highquality evidence on the use of routine thromboprophylaxis in such patients. Moreover, direct comparison of the haemostatic profiles of mildly ill COVID-19 patients and severely ill COVID-19 patients is lacking.

To address this gap, we performed this study with the aim to describe and clinically correlate haemostatic profile of COVID-19 infection in severely ill patients compared with mildly ill patients matched for age and sex, by evaluating longitudinally, their basic coagulation parameters as well as performing global haemostatic tests using Thromboelastography and Clot Waveform analysis, with the secondary objective of evaluating outcomes of thrombosis in these 2 groups of patients.

This was a prospective cohort study conducted at the National Centre for Infectious Diseases, Singapore. The study was approved by the National Healthcare Group Domain Specific Research Board (DSRB) and written informed consent obtained. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for cohort studies in the preparation of this manuscript.

Due to prevailing public health policy in Singapore, all diagnosed COVID-19 patients (including those with asymptomatic or mild COVID-19) are quarantined in hospitals or community care facilities. Patients ≥ 21 years of age who were admitted to the National Centre for Infectious Diseases, Singapore from June 2020 to January 2021 and met clinical criteria for COVID-19 with laboratory-confirmed SARS-CoV-2 infection as confirmed by PCR were screened. Patients who had either one of the following: PaO2/FiO2 ratio < 300 at screening (severe COVID- 19) or SpO2 > 95% on room air at screening without abnormal chest X ray findings (mild COVID-19), were prospectively enrolled and analysed. These criteria were adapted from the Clinical Spectrum of SARS-CoV-2 Infection [15] by the National Institutes of Health (NIH), which defines severe illness as individuals who have SpO2 < 94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300 mm Hg, respiratory frequency > 30 breaths/min, or lung infiltrates > 50%, and critical COVID-19 as individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction. Patients with mild illness can exhibit a variety of symptoms such as fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell; they do not have shortness of breath, dyspnea on exertion, or abnormal chest imaging.

Exclusion criteria included patients with the following conditions: congenital bleeding diathesis or thrombophilia, active bleeding at screening, established chronic liver failure, haemoglobin less than 7.5 g/dl within the previous 48 h, on long term anti-coagulants (patients on anti-platelet agents were not excluded) or those who were started on therapeutic anti-coagulation during their admission. However, patients who were initiated on standard dose pharmacological thromboprophylaxis i.e., subcutaneous low molecular weight heparin (LMWH) or unfractionated heparin (UFH), were not excluded. Patients had their blood samples taken on the day of recruitment as well as every 72 h till discharge or up to day 15 for both the critically ill and non-critically ill, non-oxygen dependent patients. Clinical data of a total of 20 patients recruited from June 2020 to Jan 2021 (10 severe patients compared with 10 mild patients matched for age and sex based on the above inclusion and exclusion criteria) was obtained.

Baseline patient characteristics included age, sex, ethnic group, comorbidities, and day of illness at point of enrolment. Disease severity upon recruitment was classified using the Sequential Organ Failure Assessment (SOFA) and PaO2/FiO2 ratio. Clinical data were prospectively collected including laboratory investigations, length of hospital and ICU stay, thrombotic and bleeding events and survival outcomes where available from clinical testing. Recorded interventions included the use of antivirals, systemic corticosteroids, respiratory support, and anticoagulants. Patients that survived to hospital discharge were considered survivors for the purposes of these analyses.

On recruitment (Day 0), venous blood was collected into Ethylenediaminetetraacetic acid (EDTA) tubes (Becton-Dickinson, New Jersey, USA) for baseline full blood count, and 3.2% trisodium citrate tubes for clotting factor levels, von Willebrand Factor antigen, Protein C, Protein S, anti-thrombin III. Anti-phospholipid screening was only performed for patients with a prolonged aPTT at baseline. Serial full blood count and DIC screen (comprising of PT, PTT, Fibrinogen, D-dimer), serial TEG (only for critically ill patients) and serial CWA (all patients) were performed at 3-day (± 1 day) intervals till Day 15 of recruitment (see supplementary material, Study protocol: Study schedule Table 1 ).

Coagulation tests were performed on the STA R Max Series coagulation analyzer (Diagnostica Stago, France). PT was quantified with STA Neoplastine CI Plus 10, aPTT with STACephascreen 10, fibrinogen (modified Clauss) with STA Liquid FIB, D-dimer with STA Liatest D-Di and thrombin clotting time with STA Thrombin 10. Clotting factor levels (Factors II, V, VII, VIII, IX, X, XI) were measured with STA Deficient II, V, VII, VIII, IX, X, and XI respectively. Von Willebrand factor (vWF) antigen was assayed with immunoturbidimetric method using STA Liastest vWF: Ag kit. Both assays for protein C and anti-thrombin III are functional chromogenic assays using STA Stachrom protein C and STA Stachrom ATIII kits respectively. The Protein S assay used is a functional clotting assay using a STA Staclot protein S kit. Lupus anticoagulant was performed using STA Staclot DRVV Screen, STA Staclot DRVV Confirm and PTT-LA. Anti-cardiolipin IgM and IgG were quantified using Inova test kits, and anti-B2-glycoprotein-1, Euroimmun test kit, both were performed on the Inova Quanta-lyser 3000 analyzer.

Thromboelastography was performed using (TEG) (Haemonetics, TEG6s). The TEG-6 is a microfluidic automated cartridge-based assay, where the citrated multichannel assay measures platelet-fibrin clot strength (maximal amplitude), reaction time (R time), kinetics (K, measure of time to reach 20 mm of clot strength from R) and angle (representative of the velocity of clot strength generation). Clot waveform analysis (CWA) was performed with Sysmex CN-6000 automated coagulation analyser (Sysmex Corporation, Kobe, Japan) with Dade Actin FSL (Siemens Healthcare, Marburg, Germany) for aPTT CWA and Innovin (Siemens Healthcare, Marburg, Germany) for PT CWA, as per International Society of Haemostasis and Thrombosis (ISTH) Scientific and Standardization Committee recommendation [16] . Four quantitative parameters were recorded: "Delta change" (difference between initial maximum and final maximum values of light transmittance), "Min1" (maximum velocity), "Min2" (maximum acceleration), and "Max2" (maximum deceleration).

Descriptive analyses were used to summarise the baseline characteristics and laboratory findings among the severely ill and mildly ill COVID-19 patients. For categorical data, frequencies and percentages were presented. Tests of association were performed by the Pearson's chi-square test if expected counts in all cells were 5 or more, or by the Fisher's exact test if one of the expected counts was fewer than 5. For continuous data, median and interquartile range (IQR) were presented due to its skewed distribution. Tests of association between mild COVID-19 patients and severe COVID-19 patients were performed using the Wilcoxon rank-sum test. A 2-sided p-value < 0.05 was statistically significant. All analyses were done using STATA 16.1. (Reference: StataCorp. 19. 

This prospective cohort study included 20 COVID-19 patients (10 severely or critically ill with PF ratio < 300, 10 mild COVID-19 patients) with a median age 60 (interquartile range (IQR) 49.5-64.5). The patients were predominantly male (16 out of 20 patients) with a multi-ethnic background (Chinese, Indian, Malay and Others). The patients had comorbidities of hypertension (60%), hyperlipidemia (45%), diabetes (45%) and chronic obstructive pulmonary disease (20%), with a slightly higher number of co-morbidities in mildly ill patients. The median day of haemostatic assessment of their illness was slightly earlier in mildly ill COVID-19 patients at Day 6.5 (IQR 5-8) of illness compared with severely ill patients at Day 9.5 (IQR 6-13) of illness, which is consistent with the progression of COVID-19 infection, where the onset of respiratory failure commences after the first week of illness. As per our Singapore NCID treatment guidelines for COVID- 19 [17], we used pharmacological venous thromboembolism (VTE) prophylaxis for patients with critical or severe COVID-19, as well as risk stratified mild/moderate COVID-19 patients for requirement for thromboprophylaxis using the PADUA prediction score. The median Padua prediction score on assessment was raised for severely ill patients (5 points) compared with mildly ill patients (3 points), with a median SOFA score of 2 (IQR 2-4.5 points) on ICU admission. 9 of the 10 severe patients were initiated on pharmacological thromboprophylaxis with low molecular weight heparin (enoxaparin), with 1 patient excluded due to haemorrhagic conversion of ischaemic stroke. The other group of 10 mild patients had low Padua scores and were not placed on pharmacological thromboprophylaxis. 2 of the severe patients developed thrombosis, one with proximal lower limb thrombosis and the other with ischaemic stroke with haemorrhagic conversion. No other bleeding events were noted in the other patients. The SOFA score was low on ICU admission as patients were pre-emptively admitted to ICU for high flow oxygen, preceding a planned intubation if respiratory failure worsened. The median PaO2/FiO2 ratio on admission to ICU was 194.5 (IQR 174-241) with 3 patients requiring mechanical ventilation, with 1 developing intractable respiratory failure requiring extra corporeal membrane oxygenation and eventually death. The median length of ICU stay was 8 days (IQR 5-10.5 days) for severe patients. The median length of hospital stay was 17 days (IQR 13-19 days) for severe patients and a shorter 7 days (IQR 6-11 days) for mild patients. Table 1 summarizes the demographic and clinical characteristics of these 20 Covid-19 patients.

On Day 0 of recruitment, severe patients had median haemoglobin concentration of 13.1 g/dl (IQR 12.3, 13.7), with a normal median white blood cell count of 8.1 × 10 9 /L (IQR 1.9, 6.2 g/dl), lymphopenia of 0.8 × 10 9 The median values for both mild and severe patients for Factors II, V, VII, IX, X and XI, Protein C, Protein S and anti-thrombin III were within the normal reference ranges. Tables 2 and 3 summarizes the multiple laboratory and coagulation parameters that were performed. For the mild patients, the median aPTT and PT clot waveform parameters were all within normal range throughout the 15 days of assessment. 2 mild patients who later developed consolidation on subsequent repeat chest X ray were excluded from CWA analysis, as their illness worsened, fulfilling criteria for moderate COVID-19 illness. These 2 patients demonstrated elevated delta change, clot velocity, clot acceleration and deceleration on CWA analysis. Comparison of CWA parameters between severe patients and mild patients on Day 0 of recruitment, showed in the severe group, a statistically significant higher (above the upper limit .0), median PT clot acceleration (min 2) of 3.6%/s 2 (IQR 3.2, 4.5) (p = 0.02) and clot deceleration (max2) 2.9 (IQR 2.5, 3.5) (p = 0.02) than in the mild group, which had normal median aPTT and PT delta change, clot velocity (min 1), clot acceleration (min2) and clot deceleration (max2). Over the 6 time points of assessment spread over 15 days, there was an overall declining trend in the CWA parameters (aPTT and PT) for both severe and mild patients. There was no biphasic waveform pattern present on light transmission curves of the COVID-19 patients that could suggest an underlying DIC.

At Day 0 of assessment, in severely ill patients there was a statistically significant increase in the median maximal amplitude ( For the severely ill patients, the MA for the CK, CRT and CFF channels, CK and CRT angles, and CRT and CFF A10 showed a peak in values towards Day 9 of assessment, before a decreasing trend was noted towards Day 15. Tables 4 and 5 summarizes the multiple quantitative parameters for the global haemostatic tests (CWA and TEG) that were recorded.

To our knowledge, this is the first prospective, matched study comparing conventional coagulation tests and global haemostatic tests between mild and severe COVID-19 patients. Currently there are no diagnostic criteria for COVID-19 associated coagulopathy (CAC), however three stages of CAC have been proposed by Thachil et al. [18] to aid early Stage 2 comprises of severe symptoms, requiring oxygen supplementation, progressive pulmonary inflammation, increased incidence of microthrombi and local coagulopathy and critical care support with a hypercoagulable state. Stage 3, the critically ill patient with COVID-19 has respiratory failure which may require mechanical ventilatory support or extracorporeal membranous oxygenation support. The coagulation profile may have a high D-dimer levels 6 times above upper limit of normal, hyperfibrinogenaemia, thrombocytopenia, prolonged PT, a high incidence of pulmonary and venous thrombosis, and in rare cases DIC. Our mild patients who remained in Stage 1 of CAC were non oxygen dependent, remained ambulant throughout their hospitalization and were discharged well. Upon initial assessment, they had mildly raised coagulation parameters (mildly raised median Factor VIII levels and vWF levels, with normal median D-dimer and fibrinogen levels) and normal global haemostatic tests (normal TEG and normal CWA parameters), with no elevation of median CWA parameters on repeated assessment and no elevation of baseline TEG on Day 0. They did not receive thromboprophylaxis with LMWH and no corresponding thrombotic or bleeding events were noted.

Conversely, our severe patients enrolled were in either stage 2 or 3 of CAC on their day of recruitment with the majority initiated on standard dose LMWH thromboprophylaxis. Upon initial assessment, they had markedly raised coagulation parameters (elevated median D-dimer, Fibrinogen, Factor VIII, vWF levels) indicative of a hypercoagulable Reference intervals for clot waveform parameters were established locally based on 124 healthy controls in accordance with the Clinical and Laboratory Standards Institute guidelines a Results for 1 patient only, 9 others were discharged to community care facilities b 2 COVID-19 patients progressed from mildly ill to a moderately ill state, hence their CWA parameters were excluded from the analysis state which correlated with a raised C-reactive protein (CRP) and raised white blood cell count that reflected an inflammatory state. 3 patients developed a lupus anticoagulant. Only 2 out of 10 critically ill patients developed thrombosis and 1 subsequently developed intracranial bleeding due to haemorrhagic conversion of ischaemic stroke. Our decreased rate of thrombosis observed in the severely ill group compared to higher published international rates [19] is consistent with the rates seen in a local Singapore multicentre ICU study which we performed [5] , showing lower venous thromboembolism but higher arterial thrombosis. This may be due to regional and ethnic variations, where previous studies have shown patients of Asian lineage having a lower VTE risk compared to Western cohorts [20] . Our patients were also younger with fewer comorbidities with early admission to the ICU while not requiring mechanical ventilation and started early on interventions such as high dose dexamethasone, remdesivir and tocilizumab, which may mitigate the development of a significant thrombo-inflammatory state associated with severe COVID-19.

In recent studies on CWA and COVID-19 associated hypercoagulability, CWA parameters were significantly higher in severe COVID-19 [3, 21] as compared with mild disease [22, 23] . The analysis of aPTT and PT clot waveform parameters in our severe patients showed hypercoagulability with elevated delta change, clot velocity and clot acceleration and deceleration. An elevated delta change, which corresponds to decreased light transmission due to increased clot thickness, correlates with high levels of fibrinogen that contribute to clot strength and thickness. Elevated clot velocity (min1) reflects an increased thrombin burst and elevated clot acceleration/deceleration (min2, max2) reflects enhancement of prothrombinase activity [24] , as well as the observed hyperfibrinogenaemia which enhances the speed and acceleration of clot formation. For CWA in mild COVID-19, there was no demonstrable increase in clot waveform parameters throughout the assessment. 2 patients in the mild group had their clot waveform analysis parameters excluded from analysis as they later developed chest X ray changes and desaturation (not requiring supplemental oxygenation), resulting in a progression of disease classification to moderate COVID-19. These patients had worsening of their COVID-19 illness on Day 3-6 of assessment, with elevated CWA aPTT and PT delta change, min 1, min2, max2 as well as increased fibrinogen levels, suggesting the development of clinically detectable hypercoagulability.

The use of TEG in the evaluation of CAC in critically ill COVID-19 patients was initially proposed by Panigada et al. [9] , and later affirmed by a recent systematic review [25] that showed its efficacy in identifying and evaluating a hypercoagulable state in patients with COVID-19. TEG parameters demonstrated a hypercoagulable state with decreased K (kinetic) time, increased alpha angle, increased maximal amplitude (MA) and decreased LY30 (decreased fibrinolysis), with findings suggestive of decreased time to clot initiation, increased clot strength and decreased clot breakdown.

Our evaluation of TEG performed at Day 0 of assessment for severe patients demonstrated statistically significant elevations of median values of CFF MA, CRT Angle, CRT A10 and CFF A10 above the reference ranges, compared to mild patients who had normal values. While in severe patients the CK K, CK angle, CRT K, CRT angle, CRT MA, CKH K, CKH angle, and CKH MA remained within the normal reference range, they were significantly higher in [26, 27] in hospitalized COVID-19 patients that did not achieve the intended pharmacodynamic effect, given the persistent hypercoagulability shown on TEG despite thromboprophylaxis.

Despite recommendations by the ISTH and CHEST guidelines for a universal strategy of thromboprophylaxis for all hospitalized COVID-19 patients with standard LMWH or UFH after bleeding risk assessment, our prospective matched study has not shown evidence for sustained hypercoagulability nor the need for pharmacological thromboprophylaxis in our mild, non-hypoxic, ambulant group of COVID-19 patients who do not progress beyond Stage 1 of CAC. Universal thromboprophylaxis is not without the associated bleeding risks, and implementation of this strategy may not be suitable for all patients. Tests of coagulation and global haemostatic tests demonstrate the ability to identify hypercoagulability in critically ill patients and absence of hypercoagulability in mild patients compared to laboratory coagulation tests such as PT and aPTT, which were found to be within normal range in our patients (or slightly prolonged in other studies). Comparatively, point of care global haemostatic tests such as TEG have the advantage of a shorter turnaround time than laboratory testing for Factor VIII or vWF levels. In addition, careful monitoring with coagulation and platelet function tests [28] including platelet reactivity [29] appear beneficial for early identification of high risk COVID-19 patients and for optimization of antithrombotic therapy to reduce thrombotic risk during the critical phase of disease. Based on our findings, we propose a combination of coagulation parameters (Fibrinogen, Factor VIII and D-dimer levels) and global haemostatic tests paired with Padua scoring for VTE for a more individualized approach to thrombotic risk assessment and management.

While limitations of our study include firstly, the small number of patients recruited as a single centre cohort that may limit generalizability, and secondly, the drop out of the mild COVID-19 patients at Day 9 because they were discharged well to community care facilities for isolation, we believe our comparison data sufficiently demonstrates parameters suggestive of a hypercoagulable state reflected by global haemostatic tests and conventional markers of haemostasis (fibrinogen, Factor VIII, D-dimer), as we recruited patients within the same study period and the demographics between the 2 groups were comparable. Further well-designed randomized control trials are urgently required to assess the haemostatic profile in the asymptomatic, non-hospitalized COVID-19 patients and hospitalized mild COVID-19 patients, and to evaluate the safety and efficacy of pharmacologic thromboprophylaxis in mildly ill hospitalized COVID-19 patients. Our findings suggest the use of global haemostatic tests may lead to increased sensitivity in the diagnosis of hypercoagulability and appears reasonable in assisting clinicians in the decision for thromboprophylaxis of COVID-19 patients.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s11239-021-02575-4.

COVID-19 update: Covid-19-associated coagulopathy

Severe COVID-19 and coagulopathy: a systematic review and meta-analysis

COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore

A general review of major global coagulation assays: thromboelastography, thrombin generation test and clot waveform analysis

Clot waveform analysis: Where do we stand in 2017?

Tests of global haemostasis and their applications in bleeding disorders

Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis

Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients

Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: Chest guideline and expert panel report

Middeldorp S (2021) COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

Clinical Spectrum of SARS-CoV-2 Infection (Last Updated

Srivastava a; scientific and standardization committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications

A proposal for staging COVID-19 coagulopathy

COVID-19 and Venous Thromboembolism: a Meta-analysis of Literature Studies

Wu CC: incidence of venous thromboembolism in Asian populations: a systematic review

Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability

Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities

Clot waveform of APTT has abnormal patterns in subjects with COVID-19

Update on the clot waveform analysis

The role of TEG analysis in patients with COVID-19-Associated coagulopathy: a systematic review

Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population

Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?

International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests

Platelet Reactivity and Coagulation Markers in Patients with COVID-19

The authors greatly appreciate the efforts of our fellow healthcare workers during this pandemic. Special thanks to Sysmex Corporation (Japan) and Transmedic Pte. Ltd. for their technical support.Author contributions BEF, DCL and CYW conceived the study. All authors contributed substantially to the acquisition, analysis and interpretation of data, critical revision of manuscript for important intellectual content.Funding This work was supported by a National Healthcare Group-National Centre for Infectious Diseases (NHG-NCID) COVID-19 Centre Grant (COVID19 CG0004).

The authors declare that they have no conflict of interest.Ethical approval This study was approved by the National Healthcare Group Domain Specific Review Board (DSRB ref: 2020/00633).